Immunoglobulin preparations have been applied for the treatment of infectious diseases after the appearance of antibiotic-resistant bacterial strains. Although improved preparations include biological activities of the native form of immunoglobulin G (IgG), which participates in phagocytosis by combining with complement, they are complexes of serologically heterogeneous IgG. The therapeutic effects of conventional immunoglobulin preparations are not always reliable, due to the varied contents of specific protective immunoglobulins against infections and to the absence of IgM, which has a significantly higher combining capacity with complement than does IgG. On the other hand, the existence of protective antibodies in normal human sera against several species of pathogenic bacterial strains has been reported. We describe a method to successively isolate immunoglobulins demonstrating protective effects against infections with different species of bacterial strains from pooled human sera.
MATERIALS AND METHODS
Strains. The Smith-diffuse strain of Staphylococcus auireus, strains SS-619 and SS-620, representative strains of types II and III group B streptococci, and the K-9 strain of Klebsiella pneumoniae, all described elsewhere (4, 10, 12) , were used.
Human sera. In a private clinical laboratory, residual patient sera used for clinical examinations were pooled. The number of patients and the diseases were not clear. Sera were stored at -20°C in a freezer for 4 months. They were tentatively designated no. 1 sera. After the antibody in no. 1 sera was absorbed out, primarily with the Smith-diffuse strain by the method described below, they were designated no. 2 sera. The no. 2 sera successively absorbed out by strains SS-620, SS-619, and K-9 were designated no. 3, 4, and 5 sera, respectively.
Determination of relative passive protective activity of human sera against Smith-diffuse, SS-620, SS-619, and K-9 strains in mice. Twofold serial dilutions of no. 1 sera were prepared with saline. A group offive mice received intraperi- (6) .
Determination of passive protective activities of the eluates after absorption with homologous protective antigens. To 2.0 activity units of the eluates in 1.0 ml of phosphate-buffered saline were added various amounts of homologous protective antigens and 1.0, 0.3, and 0.1 mg of Smith surface antigen or type antigens of group B streptococci. After being left at room temperature for 30 min, supernatants were obtained by centrifugation at 6,000 x g for 20 min, and 0.5-ml volumes were injected intraperitoneally into groups of five mice. Then the animals were challenged with homologous strains by the method described above.
Determination of the passive protective effect of a conventional immunoglobulin preparation against challenge infection. Venoglobulin I (Midori-Juji Pharmaceutical Co. Ltd., Tokyo), a preparation that includes biological properties of native IgG and does not contain isolated Fc fragment, was dissolved in saline, and solutions of 4, 2, 1.0, 0.5, and 0.25 mg/ml were prepared. Intraperitoneal injections of 0.5-ml volumes were made in four groups of five mice each, and 30 min later, Smith-diffuse, SS-620, SS-619, and K-9 strains suspended in mucin or saline, as noted above, were injected intraperitoneally. The numbers of deaths were recorded for 7 days after challenge. The Venoglobulin I administered was also expressed as the amount of protein.
RESULTS Passive protective effect of eluate from no. 1 sera on mice after lethal doses of Smith-diffuse strain. With the challenge infection of Smith-diffuse strain, all mice receiving 0.5 ml of 1:2 diluted no. 1 sera survived, and 60% of animals receiving 1:4 diluted no. 1 sera survived, indicating that the undiluted sera contained 2 activity units per ml. When eluates obtained by the addition of 100, 200, and 400 mg of the Smith-diffuse organisms to 100 ml of no. 1 sera were examined for their bacterial agglutination activities, the titers were 1:16, 1:160, (Table 2) .
Passive protective effect of the eluate from no. 4 sera against lethal doses of K. pneumoniae K-9. After absorbing out no. 3 sera with strain SS-619, the sera were absorbed out with K. pneumoniae K-9. The highest bacterial agglutination titer was 1:40 in eluate obtained from a combination of 200 mg of the organisms and 100 ml of no. 4 sera, whose titer was 1:2. Passive protection against challenge infection with homologous strain was shown by 0.5 ml of undiluted eluate containing 0.15 mg of protein. In these cases, no passive protective effect was observed against challenge infections with heterologous strains (Table 5 ). The original volume of the eluate was 5.4 ml, and it contained 1.20 mg of protein per ml. Therefore, eluate from 100 ml of no. 4 sera was sufficient to protect mice of approximately 0.86 kg body weight against lethal infection with strain K-9. No protection against this strain was shown by Venoglobulin I, even at a dose of 2.36 mg per mouse (Table 2) .
Immunoglobulin contents in eluates. When the three major immunoglobulin contents in the four eluates described above were quantitated, the total immunoglobulins of the eluates decreased remarkably after repeated absorption, exhibiting totals of 16.55, 9.12, 7.36, and 5.18 mg, respectively. The decreases in amounts of IgG were especially significant, but no remarkable reduction was observed in IgM after the absorption of Smith-diffuse strain (Table 6 ). The eluates from sera no. 1, 2, 3, and 4 consisted of 53.7, 81.0, 77.1, and 79.9% immunoglobulin, respectively.
Passive protective effect of the eluates in mice after absorption with the protective antigens against challenge infection with homologous strains. The experiments described above were designed to clarify whether the protective activities of antigens, respectively, against challenge infection with homologous strains. In these experiments, the eluate obtained by K. pneumoniae K-9 was not included since the protection-inducing antigen in this species of bacteria has yet to be elucidated. DISCUSSION Serum protective antibodies against relatively low-virulence bacterial strains, such as S. auireius (14) , Staphylococcus epidermidis (2), group B streptococci (1), K. pneuimoniae (3), Kiebsiella ozaenae (5), and Serratia marcescens (11) have been demonstrated in human sera. Also, we previously reported cross-protective antibodies between the Smith-diffuse strain of S. aiurelus and a strain of type Ia group B streptococci (4). Primary human sera used for the preparation of conventional immunoglobulin preparations would contain the antibodies noted above. However, immunoglobulin preparations for practical use should contain sufficient amounts of protective antibodies against causative microorganisms. In particular, opsonic immunoglobulins are required in preparations against opportunistic bacterial infections.
Initially, only IgG antibodies were obtained in the present experiments; however, extremely low protective activities were shown in the eluates against lethal infections with the bacterial strains. Extraction of native IgM has been assumed to be difficult due to the biophysical properties of the macromolecule of this protein. During the process of dissociation of antibodies from antigen-antibody complexes, considerably high protective activities were successfully extracted against four different bacterial strains in the presence 
